Published in
Future Medicine, Future Oncology, 22(11), p. 3091-3098, 2015
DOI: 10.2217/fon.15.249
Links
- ORCID
- Future Medicine
- ORCID
- ORCID
- ORCID
- [hdl.handle.net]
- [www.ncbi.nlm.nih.gov] | PDF
- [europepmc.org] | PDF
- [www.researchgate.net] | PDF
Tools
Urotensin II receptor on preoperative biopsy is associated with upstaging and upgrading in prostate cancer
,
Pierluigi Bove,
Vincenzo Altieri,
Ioman Coman,
Sisto Perdonà,
Gaetano Facchini ,
Massimiliano Berretta,
Giuseppe Di Lorenzo,
G. D. Lorenzo,
Paolo Grieco
and other authors.
Full text: Download
Abstract
Aim: A higher Gleason score was associated with a lower tumor urotensin II receptor (UTII-R) expression in prostate cancer patients. Methods: A retrospective review of formalin-fixed paraffin-embedded tumor tissue derived from those who had prostatectomy and matching biopsy specimens was conducted at six Institutions. UTII-R expression was evaluated on biopsy by immunohistochemistry. Results: A total of 58 subjects undergoing radical prostatectomy were included. At multivariate analysis, low UTII-R expression was a significant predictor of Gleason upgrading, with an odds ratio of 10.3 (95% CI: 1.55–68.4), and of pathology upstaging, with an odds ratio of 11.1 (95% CI: 1.23–100.48). Conclusions: UTII-R expression on biopsy was associated with Gleason upgrading and pathology upstaging in prostate cancer patients.